BDM-2

Cat. No.: HY-153094

CAS No.: 1643876-33-8

Molecular Formula: $C_{25}H_{30}O_4$

Molecular Weight: 394.5

Target: HIV; HIV Integrase

Pathway: Anti-infection; Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (253.49 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5349 mL	12.6743 mL	25.3485 mL
	5 mM	0.5070 mL	2.5349 mL	5.0697 mL
	10 mM	0.2535 mL	1.2674 mL	2.5349 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 integrase (IN refers to integrase) (IC_{50}=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC_{50} value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC_{50} value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity[1].

REFERENCES

[1]. Le Rouzic E, et al. Biological and structural analysis of new potent Integrase-LEDGF allosteric HIV-1 inhibitors. bioRxiv, 2023: 2023.01. 28.523533.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA